Back

Long-term efficacy and safety of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial

18 May 2025 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: Phenotyping in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Zhuang Tian

Peking Union Medical College Hospital, Beijing (China)

6 More presentations in this session

Presentation thumbnail
Sudden cardiac death HCM risk scores in apical hypertrophic cardiomyopathy: an unmet need in clinical practice
Doctor D. Da Silva Correia (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Left ventricular global deformation index, evaluating a novel echocardiographic marker for prediction of heart failure in asian patients with hypertrophic cardiomyopathy
Doctor T. Li (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Genetic influences on clinical outcomes in hypertrophic cardiomyopathy: comparative insights into MYH7, MYBPC3 and TPM1 gene mutations
Doctor M. Vilela (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
A de novo systematic literature review to identify the clinical effectiveness and safety of different treatments for patients with non-obstructive hypertrophic cardiomyopathy
Mr M. Hurst (Cardiff, GB)
Abstract Slides Video
Presentation thumbnail
Real-world clinical and economic outcomes of nonobstructive hypertrophic cardiomyopathy: a german claims data analysis
Associate Professor F. Sedaghat-Hamedani (Heidelberg, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Phenotyping in hypertrophic cardiomyopathy

The Event

Event poster

Heart Failure 2025

18 May 2025 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Long-term efficacy of mavacamten on cardiac structure and function in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: long-term extension of EXPLORER-CN trial
thumbnail
Congress Presentation
Long-term efficacy of mavacamten on health status in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: results from long-term extension of the EXPLORER-CN trial
thumbnail
Congress Presentation
Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources